3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Aspirin
4
Blood Pressure
3
Vitamin E
2
Vitamin D
2
Nutrition Assessment
2
Metformin
2
Geritol
2
Diet, Mediterranean
2
Cholecalciferol
2
phosphoribosylformylglycinamidine synthetase
1
glycidol
1
ficlatuzumab
1
beta Carotene
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Vorinostat
1
Vascular Stiffness
1
Tumor Necrosis Factor Inhibitors
1
Therapeutics
1
Sugars
1
Spironolactone
1
Resistance Training
1
Raloxifene Hydrochloride
1
Pulse Wave Analysis
1
Progestins
1
Physical Conditioning, Human
1
Omeprazole
1
Noninvasive Prenatal Testing
1
Naproxen
1
Methods
1
Lysine Acetyltransferase 5
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cardiovascular Diseases
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled